![W. Michael Korn: The FDA just granted marketing authorization for the Invitae Common Hereditary Cancers Panel.](https://oncodaily.com/pub/uploads/2023/10/IMG_3549-1-1280x1165.jpeg)
Photo from W. Michael Korn/LinkedIn
Oct 2, 2023, 18:25
W. Michael Korn: The FDA just granted marketing authorization for the Invitae Common Hereditary Cancers Panel.
W. Michael Korn, Chief Medical Officer for Oncology at Invitae, shared on LinkedIn:
“The FDA just granted marketing authorization for the Invitae Common Hereditary Cancers Panel. This is a first-in-class authorization for a DNA test capable of assessing predisposition to a multitude of cancer types – a fantastic testament to Invitae’s high-quality testing capabilities and the incredible people at Invitae who made this happen. The FDA decision is a major win for patients, providing access to high-quality testing with broad clinical utility.”
For details click here.
Source: W. Michael Korn/LinkedIn